Radiotherapy dose may not affect prognosis in ESCC patients receiving first-line chemoradiotherapy-immunotherapy: A multicenter retrospective study | Synapse
March 3, 2026Open Access
Radiotherapy dose may not affect prognosis in ESCC patients receiving first-line chemoradiotherapy-immunotherapy: A multicenter retrospective study
Puntos clave
Higher radiotherapy doses do not improve survival rates in ESCC patients receiving triple therapy, affecting treatment strategies.
The analysis indicated that higher doses showed no significant survival advantage, signaling a need for clinical reassessment.
Observational analysis of multicenter data from China revealed consistent outcomes across diverse settings for ESCC treatment.
This finding highlights possible reevaluation of radiotherapy protocols, indicating that dosage adjustments may be unnecessary in this context.
Resumen
Multicenter data from China showed that higher radiotherapy doses provide no survival benefit for ESCC patients receiving first-line triple therapy.